Trezilent Drug Interactions

Effect of Other Drugs on TREZILENT: CYP3A4 Inducer: Coadministration of TREZILENT with a strong CYP3A4 inducer may decrease alpelisib concentration [see Pharmacology: Pharmacokinetics under Actions], which may decrease alpelisib activity. Avoid coadministration of TREZILENT with strong CYP3A4 inducers.
Breast Cancer Resistance Protein Inhibitors: Coadministration of TREZILENT with a breast cancer resistance protein (BCRP) inhibitor may increase alpelisib concentration [see Pharmacology: Pharmacokinetics under Actions], which may increase the risk of toxicities. Avoid the use of BCRP inhibitors in patients treated with TREZILENT. If unable to use alternative drugs, when TREZILENT is used in combination with BCRP inhibitors, closely monitor for increased adverse reactions.
Effect of TREZILENT on Other Drugs: CYP2C9 Substrates: Coadministration of TREZILENT with CYP2C9 substrates (e.g., warfarin) may reduce plasma concentration of these drugs [see Pharmacology: Pharmacokinetics under Actions]. Closely monitor when TREZILENT is used in combination with CYP2C9 substrates where decreases in the plasma concentration of CYP2C9 substrates may reduce activity of these drugs.